{
    "Trade/Device Name(s)": [
        "Cholestech LDX\u2122 System"
    ],
    "Submitter Information": "Alere San Diego, Inc.",
    "510(k) Number": "K223179",
    "Predicate Device Reference 510(k) Number(s)": [
        "K120615",
        "K901900",
        "K932727",
        "K102700"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA",
        "CHH",
        "LBS",
        "JGY",
        "JJE"
    ],
    "Summary Letter Date": "September 20, 2023",
    "Summary Letter Received Date": "June 6, 2023",
    "Submission Date": "June 6, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345",
        "21 CFR 862.1175",
        "21 CFR 862.1705",
        "21 CFR 862.2160",
        "21 CFR 862.1475"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total cholesterol",
        "HDL cholesterol",
        "Triglycerides",
        "Glucose",
        "LDL cholesterol (calculated)",
        "Non-HDL cholesterol (calculated)",
        "TC/HDL ratio (calculated)"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "Lithium heparin-coated capillary tube",
        "Venipuncture tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Cholestech LDX Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic methodology",
        "Solid-phase technology",
        "Reflectance photometry"
    ],
    "Methodologies": [
        "Quantitative determination",
        "Enzymatic colorimetric assay"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Cassette",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Cholestech LDX\u2122 System, a portable analyzer and cassette system for quantitative measurement of total cholesterol, HDL cholesterol, triglycerides, and glucose in whole blood.",
    "Indications for Use Summary": "Quantitative determination of total cholesterol, HDL cholesterol, triglycerides, and glucose in whole blood for diagnosing and monitoring lipid, lipoprotein, and carbohydrate metabolism disorders; not for use in children under age 2.",
    "fda_folder": "Clinical Chemistry"
}